Love Julia E, Day Ryan J, Gause Justin W, Brown Raquel J, Pu Xinzhu, Theis Dustin I, Caraway Chad A, Poon Wayne W, Rahman Abir A, Morrison Brad E, Rohn Troy T
Department of Biological Sciences, Science/Nursing Building, Room 228, Boise State UniversityBoise 83725, Idaho.
University of Washington, School of MedicineSeattle 98195, WA.
Int J Physiol Pathophysiol Pharmacol. 2017 Apr 15;9(2):40-57. eCollection 2017.
Although harboring the apolipoprotein E4 () allele is a well known risk factor in Alzheimer's disease (AD), the mechanism by which it contributes to disease risk remains elusive. To investigate the role of proteolysis of apoE4 as a potential mechanism, we designed and characterized a site-directed cleavage antibody directed at position D151 of the mature form of apoE4 and E3. Characterization of this antibody indicated a high specificity for detecting synthesized recombinant proteins corresponding to the amino acid sequences 1-151 of apoE3 and E4 that would generate the 17 kDa (p17) fragment. In addition, this antibody also detected a ~17 kDa amino-terminal fragment of apoE4 following incubation with collagenase and matrix metalloproteinase-9 (MMP-9), but did not react with full-length apoE4. Application of this amino-terminal apoE cleavage-fragment (nApoECFp17) antibody, revealed nuclear labeling within glial cells and labeling of a subset of neurofibrillary tangles in the human AD brain. A quantitative analysis indicated that roughly 80% of labeled nuclei were microglia. To confirm these findings, cultured BV2 microglia cells were incubated with the amino-terminal fragment of apoE4 corresponding to the cleavage site at D151. The results indicated efficient uptake of this fragment and trafficking to the nucleus that also resulted in significant cell death. In contrast, a similarly designed apoE3 fragment showed no toxicity and primarily localized within the cytoplasm. These data suggest a novel cleavage event by which apoE4 is cleaved by the extracellular proteases, collagenase and MMP-9, generating an amino-terminal fragment that is then taken up by microglia, traffics to the nucleus and promotes cell death. Collectively, these findings provide important mechanistic insights into the mechanism by which harboring the allele may elevate dementia risk observed in AD.
尽管携带载脂蛋白E4(apoE4)等位基因是阿尔茨海默病(AD)中一个众所周知的风险因素,但其导致疾病风险的机制仍不清楚。为了研究apoE4蛋白水解作为一种潜在机制的作用,我们设计并鉴定了一种针对成熟形式的apoE4和E3中D151位点的定点切割抗体。该抗体的鉴定表明,它对检测与apoE3和E4的氨基酸序列1 - 151相对应的合成重组蛋白具有高特异性,这些重组蛋白会产生17 kDa(p17)片段。此外,该抗体在与胶原酶和基质金属蛋白酶 - 9(MMP - 9)孵育后,也检测到了apoE4的一个约17 kDa的氨基末端片段,但不与全长apoE4反应。应用这种氨基末端apoE切割片段(nApoECFp17)抗体,在人类AD大脑中发现了神经胶质细胞内的核标记以及一部分神经原纤维缠结的标记。定量分析表明,大约80%的标记核是小胶质细胞。为了证实这些发现,将培养的BV2小胶质细胞与apoE4对应于D151切割位点的氨基末端片段一起孵育。结果表明该片段被有效摄取并转运到细胞核,这也导致了显著的细胞死亡。相比之下,一个设计类似的apoE3片段没有毒性,主要定位于细胞质中。这些数据表明了一种新的切割事件,即apoE4被细胞外蛋白酶胶原酶和MMP - 9切割,产生一个氨基末端片段,然后被小胶质细胞摄取,转运到细胞核并促进细胞死亡。总的来说,这些发现为携带该等位基因可能增加AD中观察到的痴呆风险的机制提供了重要的机制性见解。